| 臺大學術典藏 |
2021-01-28T01:06:48Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Kun-Huei Yeh;Lu Y.-S.;Hsu C.-H.;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; KUN-HUEI YEH; Lu Y.-S.; Hsu C.-H.; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:47Z |
Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors
|
Lu Y.-S.;Lien H.-C.;Yeh P.-Y.;Kun-Huei Yeh;Kuo M.-L.;Kuo S.-H.;Cheng A.-L.; Lu Y.-S.; Lien H.-C.; Yeh P.-Y.; KUN-HUEI YEH; Kuo M.-L.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:45Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.;Cheng A.-L.;Hsu C.-H.;Lu Y.-S.;Hsu C.;Kun-Huei Yeh;Wu C.-Y.;Huang C.-S.;Yang C.-H.; Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; Hsu C.; KUN-HUEI YEH; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:44Z |
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells
|
Chen K.-F.; Yeh P.-Y.; KUN-HUEI YEH; Lu Y.-S.; Huang S.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:43Z |
Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation
|
Lin P.-H.;Lu Y.-S.;Lin C.-H.;Chang D.-Y.;Huang C.-S.;Cheng A.-L.;Kun-Huei Yeh; Lin P.-H.; Lu Y.-S.; Lin C.-H.; Chang D.-Y.; Huang C.-S.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:42Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.;Hsu C.-H.;Chen L.-T.;Lu Y.-S.;Lin C.-H.;Yeh P.-Y.;Jeng H.-J.;Gao M.;Kun-Huei Yeh;Cheng A.-L.; Kuo S.-H.; Hsu C.-H.; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:32Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; KUN-HUEI YEH; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-01-19T12:08:55Z |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
|
André, F.; Ciruelos, E. M.; Juric, D.; Loibl, S.; Campone, M.; Mayer, I. A.; Rubovszky, G.; Yamashita, T.; Kaufman, B.; Lu, Y. S.; Inoue, K.; Pápai, Z.; Takahashi, M.; Ghaznawi, F.; Mills, D.; Kaper, M.; Miller, M.; Conte, P. F.; Iwata, H.; Rugo, H. S. |
| 臺大學術典藏 |
2021-01-15T03:47:43Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Hsu C.; Lu Y.-S.; Chang M.-C.; Lin J.-T.; HSIU-PO WANG; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-15T03:47:26Z |
Pneumatosis coli after etoposide chemotherapy for breast cancer
|
Shih I.-L.; Lu Y.-S.; HSIU-PO WANG; Liu K.-L. |
